nach oben

Arthritis Research & Therapy

Erschienen in:

01.08.2008 | Review

Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome

verfasst von: Dina Dadabhoy, Leslie J Crofford, Michael Spaeth, I Jon Russell, Daniel J Clauw

Erschienen in: Arthritis Research & Therapy | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Researchers studying fibromyalgia strive to identify objective, measurable biomarkers that may identify susceptible individuals, may facilitate diagnosis, or that parallel activity of the disease. Candidate objective measures range from sophisticated functional neuroimaging to office-ready measures of the pressure pain threshold. A systematic literature review was completed to assess highly investigated, objective measures used in fibromyalgia studies. To date, only experimental pain testing has been shown to coincide with improvements in clinical status in a longitudinal study. Concerted efforts to systematically evaluate additional objective measures in research trials will be vital for ongoing progress in outcome research and translation into clinical practice.

Nur mit Berechtigung zugänglich

Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MB, Stark LO, Keck PE: Family study of fibromyalgia. Arthritis Rheum. 2004, 50: 944-952. 10.1002/art.20042.PubMed

Buskila D, Sarzi-Puttini P, Ablin JN: The genetics of fibromyalgia syndrome. Pharmacogenomics. 2007, 8: 67-74. 10.2217/14622416.8.1.67.PubMed

Simms RW, Roy SH, Hrovat M, Anderson JJ, Skrinar G, LePoole SR, Zerbini CA, de Luca C, Jolesz F: Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism. Arthritis Rheum. 1994, 37: 794-800. 10.1002/art.1780370603.PubMed

Yunus MB, Khan MA, Rawlings KK, Green JR, Olson JM, Shah S: Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol. 1999, 26: 408-412.PubMed

Bondy B, Spaeth M, Offenbaecher M, Glatzeder K, Stratz T, Schwarz M, de Jonge S, Kruger M, Engel RR, Farber L, Pongratz DE, Ackenheil M: The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis. 1999, 6: 433-439. 10.1006/nbdi.1999.0262.PubMed

Gürsoy S, Erdal E, Herken H, Madenci E, Alasehirli B: Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome. Rheumatol Int. 2001, 21: 58-61. 10.1007/s002960100130.PubMed

Gürsoy S, Erdal E, Herken H, Madenci E, Alasehirli B, Erdal N: Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int. 2003, 23: 104-107.PubMed

Offenbaecher M, Bondy B, de Jonge S, Glatzeder K, Kruger M, Schoeps P, Ackenheil M: Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum. 1999, 42: 2482-2488. 10.1002/1529-0131(199911)42:11<2482::AID-ANR27>3.0.CO;2-B.PubMed

Gürsoy S: Absence of association of the serotonin transporter gene polymorphism with the mentally healthy subset of fibromyalgia patients. Clin Rheumatol. 2002, 21: 194-197. 10.1007/s10067-002-8284-5.PubMed

10.

Buskila D, Cohen H, Neumann L, Ebstein RP: An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry. 2004, 9: 730-731. 10.1038/sj.mp.4001506.PubMed

11.

Yunus MB: Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol. 1992, 19: 846-850.PubMed

12.

Bell IR, Lewis DA, Brooks AJ, Schwartz GE, Lewis SE, Walsh BT, Baldwin CM: Improved clinical status in fibromyalgia patients treated with individualized homeopathic remedies versus placebo. Rheumatology (Oxford). 2004, 43: 577-582. 10.1093/rheumatology/keh111.

13.

Scharf MB, Baumann M, Berkowitz DV: The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol. 2003, 30: 1070-1074.PubMed

14.

Farber L, Stratz TH, Bruckle W, Spath M, Pongratz D, Lautenschlager J, Kotter I, Zoller B, Peter HH, Neeck G, Welzel D, Muller W: Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients. Int J Clin Pharmacol Res. 2001, 21: 1-13.PubMed

15.

Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE: A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002, 112: 191-197. 10.1016/S0002-9343(01)01089-0.PubMed

16.

Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C: A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996, 39: 1852-1859. 10.1002/art.1780391111.PubMed

17.

Gowans SE, de Hueck A, Voss S, Silaj A, Abbey SE, Reynolds WJ: Effect of a randomized, controlled trial of exercise on mood and physical function in individuals with fibromyalgia. Arthritis Rheum. 2001, 45: 519-529. 10.1002/1529-0131(200112)45:6<519::AID-ART377>3.0.CO;2-3.PubMed

18.

Jacobsen S, Danneskiold-Samsoe B, Andersen RB: Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol. 1991, 20: 294-302. 10.3109/03009749109096803.PubMed

19.

Scudds RA, McCain GA, Rollman GB, Harth M: Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol Suppl. 1989, 19: 98-103.PubMed

20.

Arnold LM, Keck PEJ, Welge JA: Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics. 2000, 41: 104-113. 10.1176/appi.psy.41.2.104.PubMed

21.

Harris RE, Gracely RH, McLean SA, Williams DA, Giesecke T, Petzke F, Sen A, Clauw DJ: Comparison of clinical and evoked pain measures in fibromyalgia. J Pain. 2006, 7: 521-527. 10.1016/j.jpain.2006.01.455.PubMed

22.

Geisser ME, Gracely RH, Giesecke T, Petzke FW, Williams DA, Clauw DJ: The association between experimental and clinical pain measures among persons with fibromyalgia and chronic fatigue syndrome. Eur J Pain. 2007, 11: 202-207. 10.1016/j.ejpain.2006.02.001.PubMed

23.

Wolfe F: The relation between tender points and fibromyalgia symptom variables: evidence that fibromyalgia is not a discrete disorder in the clinic. Annals Rheum Dis. 1997, 56: 268-271.

24.

Petzke F, Gracely RH, Park KM, Ambrose K, Clauw DJ: What do tender points measure? Influence of distress on 4 measures of tenderness. J Rheumatol. 2003, 30: 567-574.PubMed

25.

Gracely RH, Grant MA, Giesecke T: Evoked pain measures in fibromyalgia. Best Pract Res Clin Rheumatol. 2003, 17: 593-609. 10.1016/S1521-6942(03)00036-6.PubMed

26.

Jensen K, Andersen HO, Olesen J, Lindblom U: Pressure–pain threshold in human temporal region. Evaluation of a new pressure algometer. Pain. 1986, 25: 313-323. 10.1016/0304-3959(86)90235-6.PubMed

27.

Chang L, Mayer EA, Johnson T, FitzGerald LZ, Naliboff B: Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. Pain. 2000, 84: 297-307. 10.1016/S0304-3959(99)00215-8.PubMed

28.

Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH: Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain. 2003, 105: 403-413. 10.1016/S0304-3959(03)00204-5.PubMed

29.

Gibson SJ, Littlejohn GO, Gorman MM, Helme RD, Granges G: Altered heat pain thresholds and cerebral event-related potentials following painful CO₂ laser stimulation in subjects with fibromyalgia syndrome. Pain. 1994, 58: 185-193. 10.1016/0304-3959(94)90198-8.PubMed

30.

Kosek E, Hansson P: Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain. 1997, 70: 41-51. 10.1016/S0304-3959(96)03295-2.PubMed

31.

Kosek E, Ekholm J, Hansson P: Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain. 1996, 68: 375-383. 10.1016/S0304-3959(96)03188-0.PubMed

32.

Julien N, Goffaux P, Arsenault P, Marchand S: Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain. 2005, 114: 295-302. 10.1016/j.pain.2004.12.032.PubMed

33.

Staud R, Robinson ME, Vierck CJ, Price DD: Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. Pain. 2003, 101: 167-174. 10.1016/S0304-3959(02)00325-1.PubMed

34.

Lautenbacher S, Rollman GB: Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain. 1997, 13: 189-196. 10.1097/00002508-199709000-00003.PubMed

35.

Maixner W, Fillingim R, Booker D, Sigurdsson A: Sensitivity of patients with painful temporomandibular disorders to experimentally evoked pain. Pain. 1995, 63: 341-351. 10.1016/0304-3959(95)00068-2.PubMed

36.

Kosek E, Ordeberg G: Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain. 2000, 88: 69-78. 10.1016/S0304-3959(00)00310-9.PubMed

37.

Giesecke T, Gracely RH, Williams DA, Geisser M, Petzke F, Clauw DJ: The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum. 2005, 52: 1577-1584. 10.1002/art.21008.PubMed

38.

Cook DB, Lange G, Ciccone DS, Liu WC, Steffener J, Natelson BH: Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol. 2004, 31: 364-378.PubMed

39.

Koeppe C, Schneider C, Thieme K, Mense S, Stratz T, Muller W, Flor H: The influence of the 5-HT3 receptor antagonist tropisetron on pain in fibromyalgia: a functional magnetic resonance imaging pilot study. Scand J Rheumatol Suppl. 2004, 119: 24-27. 10.1080/03009740410006989.PubMed

40.

Gracely RH, Geisser ME, Giesecke T, Grant MA, Petzke F, Williams DA, Clauw DJ: Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain. 2004, 127: 835-843. 10.1093/brain/awh098.PubMed

41.

Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H, Rabiner EA, Bushnell MC, Chizh BA: Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci. 2007, 25: 3576-3582. 10.1111/j.1460-9568.2007.05623.x.PubMed

42.

Adiguzel O, Kaptanoglu E, Turgut B, Nacitarhan V: The possible effect of clinical recovery on regional cerebral blood flow deficits in fibromyalgia: a prospective study with semiquantitative SPECT. South Med J. 2004, 97: 651-655. 10.1097/00007611-200407000-00008.PubMed

43.

Kwiatek R, Barnden L, Tedman R, Jarrett R, Chew J, Rowe C, Pile K: Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum. 2000, 43: 2823-2833. 10.1002/1529-0131(200012)43:12<2823::AID-ANR24>3.0.CO;2-E.PubMed

44.

Mountz JM, Bradley LA, Modell JG, Alexander RW, Triana-Alexander M, Aaron LA, Stewart KE, Alarcon GS, Mountz JD: Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum. 1995, 38: 926-938. 10.1002/art.1780380708.PubMed

45.

Gur A, Karakoc M, Erdogan S, Nas K, Cevik R, Sarac AJ: Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol. 2002, 20: 753-760.PubMed

46.

Alanoglu E, Ulas UH, Ozdag F, Odabasi Z, Cakci A, Vural O: Auditory event-related brain potentials in fibromyalgia syndrome. Rheumatol Int. 2005, 25: 345-349. 10.1007/s00296-004-0443-3.PubMed

47.

Yoldas T, Ozgocmen S, Yildizhan H, Yigiter R, Ulvi H, Ardicoglu O: Auditory p300 event-related potentials in fibromyalgia patients. Yonsei Med J. 2003, 44: 89-93.PubMed

48.

Ozgocmen S, Yoldas T, Kamanli A, Yildizhan H, Yigiter R, Ardicoglu O: Auditory P300 event related potentials and serotonin reuptake inhibitor treatment in patients with fibromyalgia. Ann Rheum Dis. 2003, 62: 551-555. 10.1136/ard.62.6.551.PubMedCentralPubMed

49.

Sergi M, Rizzi M, Braghiroli A, Puttini PS, Greco M, Cazzola M, Andreoli A: Periodic breathing during sleep in patients affected by fibromyalgia syndrome. Eur Respir J. 1999, 14: 203-208. 10.1034/j.1399-3003.1999.14a34.x.PubMed

50.

Landis CA, Frey CA, Lentz MJ, Rothermel J, Buchwald D, Shaver JL: Self-reported sleep quality and fatigue correlates with actigraphy in midlife women with fibromyalgia. Nurs Res. 2003, 52: 140-147. 10.1097/00006199-200305000-00002.PubMed

51.

Landis CA, Lentz MJ, Rothermel J, Buchwald D, Shaver JL: Decreased sleep spindles and spindle activity in midlife women with fibromyalgia and pain. Sleep. 2004, 27: 741-750.PubMed

52.

Gold AR, Dipalo F, Gold MS, Broderick J: Inspiratory airflow dynamics during sleep in women with fibromyalgia. Sleep. 2004, 27: 459-466.PubMed

53.

Rizzi M, Sarzi-Puttini P, Atzeni F, Capsoni F, Andreoli A, Pecis M, Colombo S, Carrabba M, Sergi M: Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia?. J Rheumatol. 2004, 31: 1193-1199.PubMed

54.

Sadeh A, Acebo C: The role of actigraphy in sleep medicine. Sleep Med Rev. 2002, 6: 113-124. 10.1053/smrv.2001.0182.PubMed

55.

Korszun A, Young EA, Engleberg NC, Brucksch CB, Greden JF, Crofford LA: Use of actigraphy for monitoring sleep and activity levels in patients with fibromyalgia and depression. J Psychosom Res. 2002, 52: 439-443. 10.1016/S0022-3999(01)00237-9.PubMed

56.

Long AC, Palermao TM, Manees AM: Brief report: using actigraphy to compare physical activity levels in adolescents with chronic pain and healthy adolescents. J Pediatr Psychol. 2008, 33: 660-665. 10.1093/jpepsy/jsm136.PubMedCentralPubMed

57.

Edinger JD, Wohlgemuth WK, Krystal AD, Rice JR: Behavioral insomnia therapy for fibromyalgia patients: a randomized clinical trial. Arch Intern Med. 2005, 165: 2527-2535. 10.1001/archinte.165.21.2527.PubMed

58.

Kop WJ, Lyden A, Berlin AA, Ambrose K, Olsen C, Gracely RH, Williams DA, Clauw DJ: Ambulatory monitoring of physical activity and symptoms in fibromyalgia and chronic fatigue syndrome. Arthritis Rheum. 2005, 52: 296-303. 10.1002/art.20779.PubMed

59.

Kajantie E, Phillips DI: The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuronedocriology. 2006, 31: 151-178. 10.1016/j.psyneuen.2005.07.002.

60.

McCain GA, Tilbe KS: Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol Suppl. 1989, 19: 154-157.PubMed

61.

Crofford LJ, Young EA, Engleberg NC, Korszun A, Brucksch CB, McClure LA, Brown MB, Demitrack MA: Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun. 2004, 18: 314-325. 10.1016/j.bbi.2003.12.011.PubMed

62.

Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL: Reduced hypothalamicpituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med. 1999, 106: 534-543. 10.1016/S0002-9343(99)00074-1.PubMed

63.

Gur A, Cevik R, Nas K, Colpan L, Sarac S: Cortisol and hypothalamic–pituitary–gonadal axis hormones in follicularphase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormones. Arthritis Res Ther. 2004, 6: R232-R238. 10.1186/ar1163.PubMedCentralPubMed

64.

Griep EN, Boersma JW, de Kloet ER: Altered reactivity of the hypothalamic–pituitary–adrenal axis in the primary fibromyalgia syndrome [see comments]. J Rheumatol. 1993, 20: 469-474.PubMed

65.

Riedel W, Layka H, Neeck G: Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Zeitschr Rheumatol. 1998, 57 (Suppl 2): 81-87. 10.1007/s003930050242.

66.

Griep EN, Boersma JW, Lentjes EG, Prins AP, Korst van der JK, de Kloet ER: Function of the hypothalamic–pituitary–adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol. 1998, 25: 1374-1381.PubMed

67.

Kirnap M, Colak R, Eser C, Ozsoy O, Tutus A, Kelestimur F: A comparison between low-dose (1 μg), standard-dose (250 μg) ACTH stimulation tests and insulin tolerance test in the evaluation of hypothalamo-pituitary–adrenal axis in primary fibromyalgia syndrome. Clin Endocrinol (Oxford). 2001, 55: 455-459. 10.1046/j.1365-2265.2001.01373.x.

68.

Calis M, Gokce C, Ates F, Ulker S, Izgi HB, Demir H, Kirnap M, Sofuoglu S, Durak AC, Tutus A, Kelestimur F: Investigation of the hypothalamo-pituitary–adrenal axis (HPA) by 1 μg ACTH test and metyrapone test in patients with primary fibromyalgia syndrome. J Endocrinol Invest. 2004, 27: 42-46.PubMed

69.

Ferraccioli G, Cavalieri F, Salaffi F, Fontana S, Scita F, Nolli M, Maestri D: Neuroendocrinologic findings in primary fibromyalgia (soft tissue chronic pain syndrome) and in other chronic rheumatic conditions (rheumatoid arthritis, low back pain) [see comments]. J Rheumatol. 1990, 17: 869-873.PubMed

70.

Ataoglu S, Ozcetin A, Yildiz O, Ataoglu A: Evaluation of dexamethasone suppression test in fibromyalgia patients with or without depression. Swiss Med Wkly. 2003, 133: 241-244.PubMed

71.

Cohen H, Neumann L, Shore M, Amir M, Cassuto Y, Buskila D: Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability [see comments]. Semin Arthritis Rheum. 2000, 29: 217-227. 10.1016/S0049-0172(00)80010-4.PubMed

72.

Cohen H, Neumann L, Kotler M, Buskila D: Autonomic nervous system derangement in fibromyalgia syndrome and related disorders. Isr Med Assoc J. 2001, 3: 755-760.PubMed

73.

Martinez-Lavin M, Hermosillo AG, Rosas M, Soto ME: Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum. 1998, 41: 1966-1971. 10.1002/1529-0131(199811)41:11<1966::AID-ART11>3.0.CO;2-O.PubMed

74.

Bou-Holaigah I, Calkins H, Flynn JA, Tunin C, Chang HC, Kan JS, Rowe PC: Provocation of hypotension and pain during upright tilt table testing in adults with fibromyalgia. Clin Exp Rheumatol. 1997, 15: 239-246.PubMed

75.

Furlan R, Colombo S, Perego F, Atzeni F, Diana A, Barbic F, Porta A, Pace F, Malliani A, Sarzi-Puttini P: Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. J Rheumatol. 2005, 32: 1787-1793.PubMed

76.

Naschitz JE, Mussafia-Priselac R, Peck ER, Peck S, Naftali N, Storch S, Slobodin G, Elias N, Rosner I: Hyperventilation and amplified blood pressure response: is there a link?. J Hum Hypertens. 2005, 19: 381-387. 10.1038/sj.jhh.1001830.PubMed

77.

McBeth J, Chiu YH, Silman AJ, Ray D, Morriss R, Dickens C, Gupta A, Macfarlane GJ: Hypothalamic–pituitary–adrenal stress axis function and the relationship with chronic widespread pain and its antecedents. Arthritis Res Ther. 2005, 7: R992-R1000. 10.1186/ar1772.PubMedCentralPubMed

78.

Glass JM, Lyden A, Petzke F, Clauw D: The effect of brief exercise cessation on pain, fatigue, and mood symptom development in healthy, fit individuals. J Psychosom Res. 2004, 57: 391-398.PubMed

79.

Okifuji A, Turk DC: Sex hormones and pain in regularly menstruating women with fibromyalgia syndrome. J Pain. 2006, 7: 851-859. 10.1016/j.jpain.2006.04.005.PubMed

80.

Macfarlane TV, Blinkhorn A, Worthington HV, Davies RM, Macfarlane GJ: Sex hormonal factors and chronic widespread pain: a population study among women. Rheumatology. 2002, 41: 454-457. 10.1093/rheumatology/41.4.454.PubMed

81.

Klein R, Berg PA: High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. Eur J Med Res. 1995, 1: 21-26.PubMed

82.

Klein R, Bänsch M, Berg PA: Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendocrinology. 1992, 17: 593-598. 10.1016/0306-4530(92)90017-2.PubMed

83.

Werle E, Fischer HP, Müller A, Fiehn W, Eich W: Antibodies against serotonin have no diagnostic relevance in patients with fibromyalgia syndrome. J Rheumatol. 2001, 28: 595-600.PubMed

84.

Wilson RB, Gluck OS, Tesser JR, Rice JC, Meyer A, Bridges AJ: Antipolymer antibody reactivity in a subset of patients with fibromyalgia correlates with severity. J Rheumatol. 1999, 26: 402-407.PubMed

85.

Nishikai M, Tomomatsu S, Hankins RW, Takagi S, Miyachi K, Kosaka S, Akiya K: Autoantibodies to a 68/48 kDa protein in chronic fatigue syndrome and primary fibromyalgia: a possible marker for hypersomnia and cognitive disorders. Rheumatology. 2001, 40: 806-810. 10.1093/rheumatology/40.7.806.PubMed

86.

Vaeroy H, Helle R, Forre O, Kass E, Terenius L: Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 1988, 32: 21-26. 10.1016/0304-3959(88)90019-X.PubMed

87.

Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F: Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994, 37: 1593-1601. 10.1002/art.1780371106.PubMed

88.

Bradley LA, Alberts KR, Alarcon GS, Alexander MT, Mountz JM, Wiegent DA, Lin HG, Blalock JE, Aaron LA, Alexander RW, San Pedro EC, Martin MY, Morell AC: Abnormal brain regional cerebral blood flow and cerebrospinal fluid levels of substance P in patients and non-patients with fibromyalgia [abstract]. Arthritis Rheum. 1996, 212-Suppl 9

89.

Liu Z, Welin M, Bragee B, Nyberg F: A high-recovery extraction procedure for quantitative analysis of substance P and opioid peptides in human cerebrospinal fluid. Peptides. 2000, 21: 853-860. 10.1016/S0196-9781(00)00219-9.PubMed

90.

Evengard B, Nilsson CG, Lindh G, Lindquist L, Eneroth P, Fredrikson S, Terenius L, Henriksson KG: Chronic fatigue syndrome differs from fibromyalgia. No evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome. Pain. 1998, 78: 153-155. 10.1016/S0304-3959(98)00134-1.PubMed

91.

Sarchielli P, Alberti A, Floridi A, Gallai V: Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology. 2001, 57: 132-134.PubMed

92.

Alpar EK, Onuoha G, Killampalli VV, Waters R: Management of chronic pain in whiplash injury. J Bone Joint Surg Br. 2002, 84: 807-811. 10.1302/0301-620X.84B6.12738.PubMed

93.

Giovengo SL, Russell IJ, Larson AA: Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol. 1999, 26: 1564-1569.PubMed

94.

Vaeroy H, Sakurada T, Forre O, Kass E, Terenius L: Modulation of pain in fibromyalgia (fibrositis syndrome): cerebrospinal fluid (CSF) investigation of pain related neuropeptides with special reference to calcitonin gene related peptide (CGRP). J Rheumatol Suppl. 1989, 19: 94-97.PubMed

95.

Hocherl K, Farber L, Ladenburger S, Vosshage D, Stratz T, Muller W, Grobecker H: Effect of tropisetron on circulating catecholamines and other putative biochemical markers in serum of patients with fibromyalgia [in process citation]. Scand J Rheumatol Suppl. 2000, 113: 46-48. 10.1080/030097400446634.PubMed

96.

Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K: Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol. 1989, 19: 158-163.

97.

Wallace D, Bowman RL, Wormsley SB, Peter JB: Cytokines and immune regulation in patients with fibrositis. Arthritis Rheum. 1989, 32: 1334-1335. 10.1002/anr.1780321024.PubMed

98.

Gur A, Karakoc M, Nas K, Remzi , Cevik , Denli A, Sarac J: Cytokines and depression in cases with fibromyalgia. J Rheumatol. 2002, 29: 358-361.PubMed

99.

Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC: Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol. 1992, 19: 90-94.PubMed

100.

Larson AA, Giovengo SL, Russell IJ, Michalek JE: Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain. 2000, 87: 201-211. 10.1016/S0304-3959(00)00284-0.PubMed

101.

Wallace DJ, Wallace JB: All about Fibromyalgia. 2001, New York: Oxford University Press

102.

Staud R, Robinson ME, Price DD: Isometric exercise has opposite effects on central pain mechanisms in fibromyalgia patients compared to normal controls. Pain. 2005, 118: 176-184. 10.1016/j.pain.2005.08.007.PubMed

103.

Sandberg M, Larsson B, Lindberg LG, Gerdle B: Different patterns of blood flow response in the trapezius muscle following needle stimulation (acupuncture) between healthy subjects and patients with fibromyalgia and work-related trapezius myalgia. Eur J Pain. 2005, 9: 497-510. 10.1016/j.ejpain.2004.11.002.PubMed

104.

Montoya P, Pauli P, Batra A, Wiedemann G: Altered processing of pain-related information in patients with fibromyalgia. Eur J Pain. 2005, 9: 293-303. 10.1016/j.ejpain.2004.07.012.PubMed

105.

Laursen BS, Bajaj P, Olesen AS, Delmar C, Arendt-Nielsen L: Health related quality of life and quantitative pain measurement in females with chronic non-malignant pain. Eur J Pain. 2005, 9: 267-275. 10.1016/j.ejpain.2004.07.003.PubMed

106.

Landis CA, Lentz MJ, Tsuji J, Buchwald D, Shaver JL: Pain, psychological variables, sleep quality, and natural killer cell activity in midlife women with and without fibromyalgia. Brain Behav Immun. 2004, 18: 304-313. 10.1016/j.bbi.2003.11.001.PubMed

107.

Maquet D, Croisier JL, Demoulin C, Crielaard JM: Pressure pain thresholds of tender point sites in patients with fibromyalgia and in healthy controls. Eur J Pain. 2004, 8: 111-117. 10.1016/S1090-3801(03)00082-X.PubMed

108.

Geisser ME, Casey KL, Brucksch CB, Ribbens CM, Appleton BB, Crofford LJ: Perception of noxious and innocuous heat stimulation among healthy women and women with fibromyalgia: association with mood, somatic focus, and catastrophizing. Pain. 2003, 103: 243-250. 10.1016/S0304-3959(02)00417-7.

109.

Ernberg M, Lundeberg T, Kopp S: Effects on muscle pain by intramuscular injection of granisetron in patients with fibromyalgia. Pain. 2003, 101: 275-282. 10.1016/S0304-3959(02)00334-2.PubMed

110.

Carli G, Suman AL, Biasi G, Marcolongo R: Reactivity to superficial and deep stimuli in pateints with chronic musculoskeletal pain. Pain. 2002, 100: 259-269. 10.1016/S0304-3959(02)00297-X.PubMed

111.

Hedenberg-Magnusson B, Ernberg M, Alstergren P, Kopp S: Effect on prostaglandin E₂ and leukotriene B₄ levels by local administration of glucocorticoid in human masseter muscle myalgia. Acta Odontol Scand. 2002, 60: 29-36. 10.1080/000163502753471970.PubMed

112.

Ernberg M, Lundeberg T, Kopp S: Plasma and serotonin levels and their relationship to orofacial pain and anxiety in fibromyalgia. J Orofac Pain. 2000, 14: 37-46.PubMed

113.

Graven-Nielsen T, Aspergen Kendall S, Henriksson KG, Bengtsson M, Sorensen J, Johnson A, Gerdle B, Arendt-Nielsen L: Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain. 2000, 85: 483-4891. 10.1016/S0304-3959(99)00308-5.PubMed

114.

Ernberg M, Lundeberg T, Kopp S: Pain and allodynia/hyperalgesia induced by intramuscular injection of serotonin in patients with fibromyalgia and healthy individuals. Pain. 2000, 85: 31-39. 10.1016/S0304-3959(99)00233-X.PubMed

115.

Ernberg M, Hedenberg-Magnusson B, Alstergren P, Kopp S: The level of serotonin in the superficial masseter muscle in relation to local pain and allodynia. Life Sci. 1999, 65: 313-325. 10.1016/S0024-3205(99)00250-7.PubMed

116.

McDermid AJ, Rollman GB, McCain GA: Generalized hypervigilance in fibromyalgia: evidence of perceptual amplification. Pain. 1996, 66: 133-144. 10.1016/0304-3959(96)03059-X.PubMed

117.

Kosek E, Ekholm J, Hansson P: Increased pressure pain sensibility in fibromyalgia patients is located deep to the skin but not restricted to muscle tissue. Pain. 1995, 63: 335-339. 10.1016/0304-3959(95)00061-5.PubMed

118.

Tunks E, McCain GA, Hart LE, Teasell RW, Goldsmith CH, Rollman GB, McDermid AJ, DeShane PJ: The reliability of examination for tenderness in patients with myofascial pain, chronic fibromyalgia and controls. J Rheumatol. 1995, 22: 944-952.PubMed

119.

Wolfe F, Ross K, Anderson J, Russell IJ: Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyagia symptoms. J Rheumatol. 1995, 22: 151-156.PubMed

120.

Lautenbacher S, Rollman GB, McCain GA: Multi-method assessment of experimental and clinical pain in patients with fibromyalgia. Pain. 1994, 59: 45-53. 10.1016/0304-3959(94)90046-9.PubMed

121.

Granges G, Littlejohn G: Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. Arthritis Rheum. 1993, 36: 642-646. 10.1002/art.1780360510.PubMed

122.

Lautenschlager J, Seglias J, Bruckle W, Muller W: Comparisons of spontaneous pain and tenderness in patients with primary fibromyalgia. Clin Rheumatol. 1991, 10: 168-173. 10.1007/BF02207658.PubMed

123.

Petzke F, Harris RE, Williams DA, Clauw DJ, Gracely RH: Differences in unpleasantness induced by experimental pressure pain between patients with fibromyalgia and healthy controls. Eur J Pain. 2005, 9: 325-335. 10.1016/j.ejpain.2004.09.001.PubMed

124.

Giesecke T, Gracely RH, Grant MA, Nachemson A, Petzke F, Williams DA, Clauw DJ: Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum. 2004, 50: 613-623. 10.1002/art.20063.PubMed

125.

Giesecke T, Williams DA, Harris RE, Cupps TR, Tian X, Tian TX, Gracely RH, Clauw DJ: Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003, 48: 2916-2922. 10.1002/art.11272.PubMed

126.

Gracely RH, Petzke F, Wolf JM, Clauw DJ: Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002, 46: 1333-1343. 10.1002/art.10225.PubMed

127.

Bendtsen L, Nørregaard J, Jensen R, Olesen J: Evidence of qualitatively altered nociception in patients with fibromyalgia. Arthritis Rheum. 1997, 40: 98-102. 10.1002/art.1780400114.PubMed

128.

Lorenz J, Grasedyck K, Bromm B: Middle and long latency somatosensory evoked potentials after painful laser stimulation in patients with fibromyalgia syndrome. Electroencephalogr Clin Neurophysiol. 1996, 100: 165-168. 10.1016/0013-4694(95)00259-6.PubMed

129.

Arroyo JF, Cohen ML: Abnormal responses to electrocutaneous stimulation in fibromyalgia. J Rheumatol. 1993, 20: 1925-1931.PubMed

130.

Yunus MB, Young CS, Saeed SA, Mountz JM, Aldag JC: Positron emission tomography in patients with fibromyalgia syndrome and healthy controls. Arthritis Rheum. 2004, 51: 513-518. 10.1002/art.20544.PubMed

131.

Chang L, Berman S, Mayer EA, Suyenobu B, Derbyshire S, Naliboff B, Vogt B, FitzGerald L, Mandelkern MA: Brain responses to visceral and somatic stimuli in patients with irritable bowel syndrome with and without fibromyalgia. Am J Gastroenterol. 2003, 98: 1354-1361. 10.1111/j.1572-0241.2003.07478.x.PubMed

132.

Wik G, Fischer H, Finer B, Bragee B, Kristianson M, Fredrikson M: Retrospenial cortical deactivation during painful stimulation of fibromyalgic patients. Int J Neurosci. 2006, 116: 1-8. 10.1080/00207450690962208.PubMed

133.

Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL: Hypothalamic–pituitary–adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994, 37: 1583-1592. 10.1002/art.1780371105.PubMed

134.

Korszun A, Sackett-Lundeen L, Papadopoulos E, Brucksch C, Masterson L, Engelberg NC, Haus E, Demitrack MA, Crofford L: Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol. 1999, 26: 2675-2680.PubMed

135.

Malt EA, Olafsson S, Lund A, Ursin H: Factors explaining variance in perceived pain in women with fibromyalgia. BMC Musculoskelet Disord. 2002, 3: 12-10.1186/1471-2474-3-12.PubMedCentralPubMed

136.

Valkeinen H, Häkkinen K, Pakarinen A, Hannonen P, Häkkinen A, Airaksinen O, Niemitukia L, Kraemer WJ, Alén M: Muscle hypertrophy, strength development, and serum hormones during strength training in elderly women with fibromyalgia. Scand J Rheumatol. 2005, 34: 309-314. 10.1080/03009740510018697.PubMed

137.

Gur A, Cevik R, Sarac AJ, Colpan L, Em S: Hypothalamic–pituitary–gonadal axis and cortisol in young women with primary fibromyalgia: the potential roles of depression, fatigue, and sleep disturbance in the occurrence of hypocortisolism. Ann Rheum Dis. 2004, 63: 1504-1506. 10.1136/ard.2003.014969.PubMedCentralPubMed

138.

Lentjes EG, Griep EN, Boersma JW, Romijn FP, de Kloet ER: Glucocorticoid receptors, fibromyalgia and low back pain. Psychoneuroendocrinology. 1997, 22: 603-614. 10.1016/S0306-4530(97)00061-9.PubMed

139.

Catley D, Kaell AT, Kirschbaum C, Stone AA: A naturalistic evaluation of cortisol secretion in persons with fibromyalgia and rheumatoid arthritis. Arthritis Care Res. 2000, 13: 51-61. 10.1002/1529-0131(200002)13:1<51::AID-ART8>3.0.CO;2-Q.PubMed

140.

McLean SA, Williams DA, Harris RE, Kop WJ, Groner KH, Ambrose K, Lyden AK, Gracely RH, Crofford LJ, Geisser ME, Sen A, Biswas P, Clauw DJ: Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum. 2005, 52: 3660-3669. 10.1002/art.21372.PubMed

141.

Weissbecker I, Floyd A, Dedert E, Salmon P, Sephton S: Childhood trauma and diurnal cortisol disruption in fibromyalgia syndrome. Psychoneuroendocrinology. 2006, 31: 312-324. 10.1016/j.psyneuen.2005.08.009.PubMed

142.

Dedert EA, Studts JL, Weissbecker I, Salmon PG, Banis PL, Sephton SE: Religiosity may help preserve the cortisol rhythm in women with stress-related illness. Int J Psychiatry Med. 2004, 34: 61-77. 10.2190/2Y72-6H80-BW93-U0T6.PubMed

143.

Sephton SE, Studts JL, Hoover K, Weissbecker I, Lynch G, Ho I, McGuffin S, Salmon P: Biological and psychological factors associated with memory function in fibromyalgia syndrome. Health Psychol. 2003, 22: 592-597. 10.1037/0278-6133.22.6.592.PubMed

144.

Maes M, Lin A, Bonaccorso S, van Hunsel F, Van Gastel A, Delmeire L, Biondi M, Bosmans E, Kenis G, Scharpé S: Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand. 1998, 98: 328-335. 10.1111/j.1600-0447.1998.tb10092.x.PubMed

145.

Torpy DJ, Papanicolaou DA, Lotsikas AJ, Wilder RL, Chrousos GP, Pillemer SR: Responses of the sympathetic nervous system and the hypothalamic–pituitary–adrenal axis to interleukin-6: a pilot study in fibromyalgia. Arthritis Rheum. 2000, 43: 872-880. 10.1002/1529-0131(200004)43:4<872::AID-ANR19>3.0.CO;2-T.PubMed

Titel: Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome
verfasst von: Dina Dadabhoy
Leslie J Crofford
Michael Spaeth
I Jon Russell
Daniel J Clauw
Publikationsdatum: 01.08.2008
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 4/2008
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar2443

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

Intervertebral disc cells as competent phagocytes in vitro: implications for cell death in disc degeneration

Human palatine tonsil: a new potential tissue source of multipotent mesenchymal progenitor cells

Disruption of the thrombospondin-2 gene alters the lamellar morphology but does not permit vascularization of the adult mouse lumbar disc

Increased susceptibility to collagen-induced arthritis in female mice carrying congenic Cia40/Pregq2 fragments

Biochemical markers of bone turnover and their association with bone marrow lesions